Novartis AG ADR (NVS)vsPrime Medicine, Inc. Common Stock (PRME)
NVS
Novartis AG ADR
$148.38
-2.52%
HEALTHCARE · Cap: $289.19B
PRME
Prime Medicine, Inc. Common Stock
$3.06
-11.82%
HEALTHCARE · Cap: $489.47M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1402428% more annual revenue ($56.58B vs $4.03M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
PRME
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
-38.5%
Fair Value
$2.49
Current Price
$3.06
$0.57 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PRME
PRME has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PRME
The primary concerns for PRME are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while PRME is a value play — different risk/reward profiles.
PRME carries more volatility with a beta of 2.31 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 19/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Prime Medicine, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Prime Medicine, Inc. is a leading biotechnology company pioneering advancements in genetic medicine through its proprietary Prime Editing technology, which facilitates precise DNA modifications. The company has developed a robust pipeline aimed at addressing severe diseases, including genetic disorders and various cancers, positioning it to meet substantial unmet medical needs. With a strong foundation of intellectual property and a clear vision for transformative therapeutic solutions, Prime Medicine is positioned for significant growth, potentially redefining treatment paradigms within the biopharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?